SI2091537T1 - Farmacevtski sestavki za zdravljenje kapilarne arteriopatije - Google Patents
Farmacevtski sestavki za zdravljenje kapilarne arteriopatijeInfo
- Publication number
- SI2091537T1 SI2091537T1 SI200731292T SI200731292T SI2091537T1 SI 2091537 T1 SI2091537 T1 SI 2091537T1 SI 200731292 T SI200731292 T SI 200731292T SI 200731292 T SI200731292 T SI 200731292T SI 2091537 T1 SI2091537 T1 SI 2091537T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- pharmaceutical compositions
- capillary arteriopathy
- arteriopathy
- capillary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06024308 | 2006-11-23 | ||
EP06025263 | 2006-12-06 | ||
PCT/EP2007/010360 WO2008061805A1 (de) | 2006-11-23 | 2007-11-23 | Pharmazeutische zusammensetzungen zur behandlung von kapillarer arteriopathie |
EP07846885.7A EP2091537B1 (de) | 2006-11-23 | 2007-11-23 | Pharmazeutische zusammensetzungen zur behandlung von kapillarer arteriopathie |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2091537T1 true SI2091537T1 (sl) | 2013-10-30 |
Family
ID=38982525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731292T SI2091537T1 (sl) | 2006-11-23 | 2007-11-23 | Farmacevtski sestavki za zdravljenje kapilarne arteriopatije |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090325997A1 (sl) |
EP (1) | EP2091537B1 (sl) |
JP (1) | JP5407865B2 (sl) |
AU (1) | AU2007324706B2 (sl) |
CA (1) | CA2670846C (sl) |
CY (1) | CY1114364T1 (sl) |
DK (1) | DK2091537T3 (sl) |
ES (1) | ES2425581T3 (sl) |
HR (1) | HRP20130791T1 (sl) |
PL (1) | PL2091537T3 (sl) |
PT (1) | PT2091537E (sl) |
RU (1) | RU2463048C2 (sl) |
SI (1) | SI2091537T1 (sl) |
WO (1) | WO2008061805A1 (sl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2550959A1 (de) | 2011-07-27 | 2013-01-30 | Sinoxa Pharma | Lisurid, Tergurid und Derivate davon zur Verwendung in der Prophylaxe und/oder Therapie fibrotischer Veränderungen |
DE102010051391A1 (de) | 2010-11-11 | 2012-10-11 | Sinoxa Pharma Ug | Multivalente Arzneistoffe mit kombinierter antioxidativer Wirkung und antagonistischen Effekten an 5-HT2-Rezeptor-Subtypen zur Behandlung von fibrotischem Organumbau. |
BR112013011640A2 (pt) * | 2010-11-11 | 2017-10-10 | Sinoxa Pharma Ug | lisurida, tergurida e derivados das mesmas para o uso na profilaxia e/ou na terapia de alterações fibróticas |
RU2516921C1 (ru) * | 2013-04-08 | 2014-05-20 | Общество с ограниченной ответственностью "Научно-производственная компания ВИТАФОРМ" | Композиция для костной пластики (варианты) |
BR112017015487A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo |
EP3804724B1 (en) * | 2016-10-20 | 2022-12-07 | Pfizer Inc. | Cdk inhibitors for treating pah |
WO2018223065A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
WO2023107931A1 (en) * | 2021-12-06 | 2023-06-15 | Terran Biosciences, Inc. | Salt and solid forms of indole analogs and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3410218A1 (de) * | 1984-03-16 | 1985-09-19 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Tergurid als antihypertensivum |
DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
IT1252163B (it) * | 1991-12-03 | 1995-06-05 | Poli Ind Chimica Spa | Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica |
US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
US20020122773A1 (en) * | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
WO2002094238A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of anti-migraine compounds through an inhalation route |
JP2005508220A (ja) * | 2001-10-24 | 2005-03-31 | パーリ・ゲーエムベーハー | 薬用組成物調製用具 |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
EP1900737A1 (en) * | 2006-08-31 | 2008-03-19 | Novartis AG | Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide |
US8580801B2 (en) * | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
BR112013011640A2 (pt) * | 2010-11-11 | 2017-10-10 | Sinoxa Pharma Ug | lisurida, tergurida e derivados das mesmas para o uso na profilaxia e/ou na terapia de alterações fibróticas |
-
2007
- 2007-11-23 PT PT78468857T patent/PT2091537E/pt unknown
- 2007-11-23 DK DK07846885.7T patent/DK2091537T3/da active
- 2007-11-23 WO PCT/EP2007/010360 patent/WO2008061805A1/de active Application Filing
- 2007-11-23 PL PL07846885T patent/PL2091537T3/pl unknown
- 2007-11-23 JP JP2009537565A patent/JP5407865B2/ja not_active Expired - Fee Related
- 2007-11-23 EP EP07846885.7A patent/EP2091537B1/de active Active
- 2007-11-23 CA CA2670846A patent/CA2670846C/en not_active Expired - Fee Related
- 2007-11-23 RU RU2009123401/15A patent/RU2463048C2/ru not_active IP Right Cessation
- 2007-11-23 SI SI200731292T patent/SI2091537T1/sl unknown
- 2007-11-23 US US12/515,966 patent/US20090325997A1/en not_active Abandoned
- 2007-11-23 AU AU2007324706A patent/AU2007324706B2/en not_active Ceased
- 2007-11-23 ES ES07846885T patent/ES2425581T3/es active Active
-
2012
- 2012-01-20 US US13/354,832 patent/US9695173B2/en not_active Expired - Fee Related
-
2013
- 2013-08-20 CY CY20131100707T patent/CY1114364T1/el unknown
- 2013-08-21 HR HRP20130791TT patent/HRP20130791T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2670846C (en) | 2014-12-23 |
PT2091537E (pt) | 2013-08-29 |
RU2009123401A (ru) | 2010-12-27 |
JP5407865B2 (ja) | 2014-02-05 |
JP2010510273A (ja) | 2010-04-02 |
US20090325997A1 (en) | 2009-12-31 |
DK2091537T3 (da) | 2013-08-26 |
ES2425581T3 (es) | 2013-10-16 |
US20140045879A1 (en) | 2014-02-13 |
EP2091537B1 (de) | 2013-05-22 |
HRP20130791T1 (en) | 2013-09-30 |
RU2463048C2 (ru) | 2012-10-10 |
CY1114364T1 (el) | 2016-08-31 |
AU2007324706A1 (en) | 2008-05-29 |
PL2091537T3 (pl) | 2013-10-31 |
AU2007324706A2 (en) | 2009-06-25 |
AU2007324706B2 (en) | 2013-09-05 |
US9695173B2 (en) | 2017-07-04 |
CA2670846A1 (en) | 2008-05-29 |
WO2008061805A1 (de) | 2008-05-29 |
EP2091537A1 (de) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2107909A4 (en) | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC DISORDERS | |
HRP20130791T1 (en) | Pharmaceutical compositions for the treatment of capillary arteriopathy | |
GB0522311D0 (en) | Pharmaceutical compositions for the treatment of pain | |
EP2001498A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
IL194176A0 (en) | Pharmaceutical compositions | |
IL198380A0 (en) | Gas-enriched fluid compositions for wound healing | |
GB0625322D0 (en) | Pharmaceutical compositions | |
ZA200900347B (en) | Preparation of pharmaceutical compositions | |
HK1138732A1 (en) | Pharmaceutical compositions | |
IL192415A0 (en) | Pharmaceutical composition for the treatment of nail diseases | |
IL209360A (en) | Medications containing pm00104 for the treatment of multiple myeloma | |
IL179337A0 (en) | Pharmaceutical compositions for the treatment of pruritus | |
EP2114374A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE | |
EP2124959A4 (en) | PHARMACEUTICAL COMPOSITION | |
IL194066A0 (en) | Therapeutic composition for treatment of tinnitus | |
HUP0500947A2 (en) | Composition for treatment of paradontosis | |
IL176303A0 (en) | Pharmaceutical composition for the treatment of otomycosis | |
GB0619891D0 (en) | Pharmaceutical composition of risedronate | |
ZA200807154B (en) | Liquid treatment composition | |
EP2149549A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS | |
HUP0500948A2 (en) | Composition for treatment of diabeticus paradontosis | |
HK1129593A1 (en) | Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia kcnq- | |
GB0617578D0 (en) | Pharmaceutical composition | |
GB0612696D0 (en) | Pharmaceutical composition | |
GB0600032D0 (en) | Pharmaceutical composition |